Herbst + Pattern: 2023 Disruptive Technology Award

Pattern Bioscience, Inc., (Pattern) an innovator in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, and Santa Cruz-based Herbst Produkt (Herbst) today announced that it was named the winner of the 2023 Disruptive Technology Award from the Association for Diagnostics & Laboratory Medicine (ADLM, formerly known as AACC). Pattern was chosen by a panel of expert judges in diagnostic testing and healthcare technologies.

Pattern is pioneering the use of single-cell microbiology to rapidly diagnose drug-resistant bacterial infections and identify effective treatments. Its unique rapid phenotypic test platform, based on single-cell analysis of microorganisms combined with machine learning, can generate clinically actionable data identifying the causal pathogen and profiling its antibiotic susceptibility in hours — rather than the days required for the current standard of culture-based tests. The company’s first test will be for patients with pneumonia.

Herbst + Pattern

The incredible team at Austin-based Pattern has been working with Herbst since 2018 to design and develop a groundbreaking diagnostic platform that will improve the accuracy of the world’s most important health decisions. This award goes to their first commercial application, which can detect pneumonia and identify the antibiotic course of treatment in a blazingly-fast four to six hours, compared with the three days required for traditional culture testing. Pattern’s speed and accuracy is unmatched and has the ability to save the lives of critically ill patients around the world.

Herbst and Pattern formed a design partnership has included the complete design of the Pattern system, diagnostic hardware, test cartridges, the Pattern brand (and name!), packaging, website and even their super hip HQ in Austin.